Sooner or later, every man in Australia runs into problems with impotency buy viagra australia like other bodily functions, must be in order.

Sywg.com.hk

A-share research
Monday, 10 November, 2014 Bringing China to the World Zhejiang Huahai Pharmaceutical (600521:CH)
Unchanged
Zhejiang Huahai Pharmaceutical Co Ltd
Seeking approval
Sector: Health Care
Industry: Pharmaceuticals
Sub-Industry: Pharmaceuticals

Zhejiang Huahai Pharmaceutical received prior approval supplement (PAS) from the US Food and Drug Administration (FDA) to order to provide bulk pharmaceutical chemicals (BPC) to its lisinopril preparation products. Market Cap (Rmbm) Lisinopril tablets are one of the top 20 generic drugs in the US market, with Indian Market Cap (US$m) company Lupin (LPC:IN) occupying the largest market share over the past few years. Shares outstanding (m) Despite Zhejiang Huahai Pharmaceutical's purchase of the abbreviated new drug application (ANDA) of lisinopril tablets, this was challenged by Lupin due to high costs generated by its European BPC supplier. Having acquired the PAS, we expect the company Dividend yield (FY13) to reduce its costs and regain its market share from Lupin in the US, where Zhejiang Huahai Pharmaceutical has established a mature business model. In addition, in a bid to reduce its costs, the company has changed suppliers for other BPC including levetiracetam Inst Ownership (Top 5)
and lisinopril tablets. Before the FDA launched new standards of BPC in June 2014, generic pharmaceutical PICC PROPERTY & CASU manufacturers submitted a numerous ANDAs. As a result, many generic drugs were listed on the apparaisals queue and the US market experienced supply shortages of related Source: Bloomberg drugs. According to its application schedule, we believe Zhejiang Huahai Pharmaceutical is likely to receive several ANDA approvals for risperidone, bupropion hydrochloride sustained-release tablets over the next three to six months. This represents potential earnings growth in 15E. Due to production limitations in the company's industrial park, BPC processing experienced a setback in 9M14. However, we expect this to ease in 4Q14. Successful exports of lamotrigine prove the company's mature overseas business model. With more approvals, we forecast increasing preparation exports. We forecast EPS of Rmb0.41 (-11% YoY) in 14E, Rmb0.51 (+26% YoY) in 15E and Rmb0.66 (+28% YoY) in 16E. The stock is trading at 37x 14E PE, 29x 15E PE and 23x 16E PE. Maintain BUY. Financial Table
Operating revenue Gross margin (%) Source: SWS Research Source: Bloomberg A-share research
Monday, 10 November, 2014 Bringing China to the World Information Disclosure
The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed. Undertakings of the Analyst
I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein. Disclosure with respect to the Company
The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065. Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contacor the relevant disclosure materials or log intor the analysts' qualifications,the arrangement of the quiet period and the affiliates' shareholdings. Introduction of Share Investment Rating
Security Investment Rating
When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows: Buy: with a markup more than 20% better than that of the market; Outperform:With a markup 5% to 20% better than that of the market; Neutral: with a markup less than 5% better or worse than that of the market; Underperform: with a markup more than 5% worse than that of the market. Industry Investment Rating: When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows: Overweight:Industry performs better than that of the whole market; Equal weight: Industry performs about the same as that of the whole market; Underweight:Industry performs worse than that of the whole market. We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested. HSCEI is the benchmark employed in this report. A-share research
Monday, 10 November, 2014 Bringing China to the World This report is to be used solely by the clients of SWS Research Co., Ltd. (hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report. This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments. The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website The clients may ask for follow-up explanations if they so wish. The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein. Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services. The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary. Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment. Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company. The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company. This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies. This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO). This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents. A-share research
Monday, 10 November, 2014 Bringing China to the World Disclaimer :
This report was prepared, approved, published and distributed by the SWS Research Co., Ltd located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036). Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information. Analyst Certification
Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Important US Regulatory Disclosures on Subject Companies
This material was produced by SWS Research Co., Ltd solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd or an authorized affiliate of SWS Research Co., Ltd This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd or its Affiliates consider to be reliable. None of SWS Research Co., Ltd Limited accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. 1. SWS Research Co., Ltd or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report. 2. SWS Research Co., Ltd or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months. 3. SWS Research Co., Ltd Limited or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months. 4. However, one or more person of SWS Research Co., Ltd or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients. 5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities. 6. SWS Research Co., Ltd or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report. Distribution in Singapore
If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report."

Source: http://www.sywg.com.hk/research/report.php?n=37713919281201411110825168

bhecbm00000.web704.discountasp.net

GUIDELINES FOR BERMUDA2011 GOVERNMENT OF BERMUDAMinistry of HealthDepartment of Health HYPERTENSION GUIDELINES FOR BERMUDA Government of Bermuda Ministry of Health Department of Health P.O. Box HM 1195, Hamilton HM EX Bermuda Hypertension Task Group Hypertension Task Group (2011) Hypertension Guidelines for Bermuda

20110202.23_25.tp

Article in press - uncorrected proof J. Perinat. Med. 41 (2013) 23-25 • Copyright  by Walter de Gruyter • Berlin • Boston. DOI 10.1515/JPM.2011.115 Optimization of women's health before conception whenpregnancy has been postponed Joachim W. Dudenhausen1, Amos Grunebaum1 and rarely features in the public debate. The data in the literature